Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer
- 1 June 2010
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 292 (1) , 32-40
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological ActivitiesScience Signaling, 2008
- Gene Transfer of Matrix Metalloproteinase-9 Induces Tumor Regression of Breast CancerIn vivoCancer Research, 2008
- Emerging roles of proteases in tumour suppressionNature Reviews Cancer, 2007
- The other side of MMPs: Protective roles in tumor progressionCancer and Metastasis Reviews, 2007
- Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancerCancer, 2007
- Estradiol and Tamoxifen Regulate Endostatin Generation via Matrix Metalloproteinase Activity in Breast CancerIn vivoCancer Research, 2006
- Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapyNature Reviews Cancer, 2006
- Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factorGynecologic Oncology, 2005
- Tamoxifen Therapy for Ovarian Cancer in the Adjuvant and Advanced Settings: Systematic Review of the Literature and Implications for Future ResearchGynecologic Oncology, 2002
- Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary ReportGynecologic Oncology, 1996